Evaluating Synbiotic Supplement Capsules to Reduce Inflammation and Improve Nutrition in Adults Undergoing Peritoneal Dialysis for Chronic Kidney Disease

What this Trial Is About

Researchers are evaluating whether synbiotics, a combination of probiotics and prebiotics, can reduce inflammation and improve nutrition in adults with chronic kidney disease who are undergoing peritoneal dialysis. This randomized, controlled, double-blind trial compares synbiotic capsules to placebo capsules to see if they lower inflammation markers in the blood, improve nutritional status, and reduce peritonitis episodes. Participants are randomly assigned to receive either a daily synbiotic capsule containing specific probiotic strains and prebiotic fibers or a daily placebo capsule with no active ingredients. This treatment lasts for 6 months, with capsules taken each morning before meals. The study includes clinical and biochemical assessments at baseline, 3 months, and 6 months, during which blood tests and nutritional evaluations are performed. During the trial, participants visit the clinic three times for blood draws and nutrition checkups. Researchers measure markers like high-sensitivity C-reactive protein, erythrocyte sedimentation rate, p-cresyl sulfate, and indoxyl sulfate to assess inflammation and toxins. Nutritional status is evaluated using the Malnutrition-Inflammation Score, and occurrences of peritonitis are recorded. Adherence is monitored through pill counts and reminder calls. The total participation lasts 6 months.

Probiotic and Prebiotic Supplementation in Peritoneal Dialysis Patients